Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814199 | 0.83 | MCL1 (0.43) | EDNRAMCL1KDM4EAHRGPR35 | |
| SCHEMBL3607819 | 0.82 | EDNRA (0.60) | EDNRAMCL1KDM4EELANEGPR35 | |
| SCHEMBL1474620 | 0.82 | GABRA1 (0.47) | EDNRAMCL1KDM4EAHRELANE | |
| SCHEMBL11194764 | 0.79 | EDNRA (0.43) | EDNRAMCL1KDM4EELANEGPR35 | |
| SCHEMBL28509698 | 0.78 | EDNRA (0.52) | EDNRAMCL1KDM4ENPC1MAPT | |
| SCHEMBL17786596 | 0.73 | KDM4E (0.46) | EDNRAMCL1KDM4ENPC1KMT2A | |
| SCHEMBL27593837 | 0.71 | EDNRA (0.59) | EDNRAMCL1KDM4EGPR35NPC1 | |
| SCHEMBL1474617 | 0.71 | MAPT (0.52) | EDNRAMCL1KDM4EGPR35NPC1 | |
| SCHEMBL6830612 | 0.71 | KCNA5 (0.48) | KDM4EELANEGPR35MAPTKMT2A | |
| SCHEMBL11881889 | 0.71 | EDNRA (0.41) | EDNRAMCL1KDM4EAHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233174-A1 | BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615849-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615578-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| CN-120202206-A | Cyclic benzimidazole derivatives as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-06-13 | — | — | US | disclosed |
| WO-2024099908-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099907-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| EP-2417140-B1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| EP-2417140-A1 | INHIBITORS OF HIV REPLICATION | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | EDNRA 3048/4885MCL1 3259/4885KDM4E 2028/4885 |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | CGAS, STING1, IRF3 | EDNRA 1426/4885MCL1 3763/4885KDM4E 1598/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | EDNRA 1800/4885MCL1 1776/4885KDM4E 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.